Citadel Advisors
KYMR icon

Citadel Advisors’s Kymera Therapeutics KYMR Stock Holding History

Citadel Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Buy
27,200
+16,000
+143% +$1.27M ﹤0.01% 5827
2025
Q4 		$871K Sell
11,200
-11,400
-50% -$770K ﹤0.01% 7705
2025
Q3 		$1.28M Sell
22,600
-10,900
-33% -$492K ﹤0.01% 7007
2025
Q2 		$1.46M Buy
33,500
+21,700
+184% +$747K ﹤0.01% 6314
2025
Q1 		$323K Sell
11,800
-9,400
-44% -$343K ﹤0.01% 9414
2024
Q4 		$853K Sell
21,200
-3,400
-14% -$154K ﹤0.01% 7388
2024
Q3 		$1.16M Buy
24,600
+2,000
+9% +$88.3K ﹤0.01% 6560
2024
Q2 		$675K Sell
22,600
-10,200
-31% -$353K ﹤0.01% 7426
2024
Q1 		$1.32M Buy
32,800
+16,600
+102% +$594K ﹤0.01% 6364
2023
Q4 		$412K Buy
16,200
+700
+5% +$12.5K ﹤0.01% 8503
2023
Q3 		$215K Sell
15,500
-10,100
-39% -$203K ﹤0.01% 9753
2023
Q2 		$589K Sell
25,600
-5,800
-18% -$166K ﹤0.01% 7574
2023
Q1 		$930K Sell
31,400
-68,100
-68% -$2.2M ﹤0.01% 6938
2022
Q4 		$2.48M Buy
99,500
+35,900
+56% +$957K ﹤0.01% 5083
2022
Q3 		$1.39M Sell
63,600
-102,200
-62% -$2.69M ﹤0.01% 6313
2022
Q2 		$3.27M Buy
165,800
+144,800
+690% +$3.38M ﹤0.01% 4599
2022
Q1 		$889K Buy
21,000
+17,600
+518% +$743K ﹤0.01% 7980
2021
Q4 		$216K Sell
3,400
-300
-8% -$17.5K ﹤0.01% 11684
2021
Q3 		$217K Buy
+3,700
New +$215K ﹤0.01% 11816

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Citadel Advisors's KYMR Position: Q1 2026 in Review

Citadel Advisors reduced its Kymera Therapeutics (KYMR) stake by 26% in Q1 2026, selling an estimated $3.27M and leaving 118,597 shares worth $9.88M. The position accounts for ﹤0.01% of the portfolio, ranked #3274.

Citadel Advisors first reported a position in KYMR in Q1 2021 and has held it in 20 quarters since. The position peaked at $22.6M in Q2 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Citadel Advisors held 118,597 shares of Kymera Therapeutics worth $9.88M as of Q1 2026.
  • Citadel Advisors sold 41,268 Kymera Therapeutics shares in Q1 2026, an estimated $3.27M.
  • Kymera Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3274 holding.
  • Citadel Advisors first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Citadel Advisors's Kymera Therapeutics position peaked at $22.6M in Q2 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.